Ownership history in Centiva Capital, LP Β· 4 quarters on record
This page tracks every 13F SEC filing in which Centiva Capital, LP reported a position in ABCELLERA BIOLOGICS INC (ABCL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Centiva Capital, LP underperformed the S&P 500 by β81.7% annually on this ABCL position. Timing score: 0% (0/3 decisions correct). Average cost basis: $8.10. Maximum drawdown during holding period: β93.4%.
β Significantly underperformed the S&P 500 by 81.7% ann.
3 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
0 of 3 add/trim decisions correct
Best entry: $2.93 (2024 Q4) Β· Worst: $33.96 (2021 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
3 adds Β· 1 trim. Bought during 1 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size